Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Grows By 29.1%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 40,313 shares, a growth of 29.1% from the December 15th total of 31,224 shares. Based on an average trading volume of 25,648 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.1% of the company’s stock are short sold. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 25,648 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NBTX shares. Wall Street Zen raised Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $11.00.

Nanobiotix Trading Down 0.9%

Shares of NASDAQ:NBTX traded down $0.18 during trading on Friday, reaching $20.99. The company had a trading volume of 13,553 shares, compared to its average volume of 34,376. Nanobiotix has a fifty-two week low of $2.95 and a fifty-two week high of $30.35. The stock’s fifty day moving average price is $21.57 and its 200 day moving average price is $15.71.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.